ASP3026 D17-109 is a potent inhibitor of

is a potent inhibitor of the CK1 isoforms CK1ε and CK1δ (IC50 = 7

Smiles: CC(C)(O)C(O)CC[C@@H](C)[C@H]1CC[C@H]2/C(/CCC[C@@]21C)=C/C=C1/C[C@@H](O)C[C@H](O)C/1=C

is selective CB2 receptor agonist

InChiKey: GWHQHAUAXRMMOT-MBANBULQSA-N

methylthioninium chloride

ASP3026 D17-109 is a potent inhibitor ofASP3026 is a novel and selective inhibitor for the ALK kinase. ASP3026 potently inhibited ALK kinase activity and was more selective than crizotinib in a Tyr kinase panel. In an anchorage independent in vitro cell growth assay, ASP3026 inhibited the growth of NCI H2228, a human NSCLC tumor cell line endogenously expressing EML4 ALK variant 3 and that of 3T3 cells expressing EML4 ALK variant 1, 2 and 3. The plasma and tumor concentrations of ASP3026 in